|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| License and collaborations revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Acquired in-process research and development | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Financing costs (Note 8) | |||||
| Interest expense (Note 4) | |||||
| Fair value change in warrant and other derivative liabilities | |||||
| Financing costs (Note 7) | |||||
| Interest expense | |||||
| Other income, net | |||||
| Loss before income taxes | |||||
| Provision for income taxes | |||||
| Net loss | |||||
| Other comprehensive loss, net of tax | |||||
| Comprehensive loss | |||||
| Net loss per share (Note 11): | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Number of shares used in per share calculations: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...